INmune Bio (INMB) Competitors

INmune Bio (NASDAQ:INMB) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Do institutionals and insiders have more ownership in INMB or LFCR?

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 35.7% of INmune Bio shares are held by company insiders. Comparatively, 32.2% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more volatility and risk, INMB or LFCR?

INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Does the media refer more to INMB or LFCR?

In the previous week, INmune Bio had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for INmune Bio and 4 mentions for Lifecore Biomedical. INmune Bio's average media sentiment score of 0.58 beat Lifecore Biomedical's score of 0.38 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is INMB or LFCR more profitable?

INmune Bio has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -31.70%. INmune Bio's return on equity of -120.62% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-120.62%	-92.94%
Lifecore Biomedical	-31.70%	-846.51%	-13.03%

Do analysts prefer INMB or LFCR?

INmune Bio presently has a consensus price target of $18.40, suggesting a potential upside of 627.27%. Lifecore Biomedical has a consensus price target of $8.00, suggesting a potential upside of 8.55%. Given INmune Bio's stronger consensus rating and higher probable upside, research analysts clearly believe INmune Bio is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has higher earnings & valuation, INMB or LFCR?

Lifecore Biomedical has higher revenue and earnings than INmune Bio. Lifecore Biomedical is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$10K	6,724.74	-$42.08M	-$2.48	-1.02
Lifecore Biomedical	$128.87M	2.14	-$38.72M	-$1.31	-5.63

Summary

INmune Bio beats Lifecore Biomedical on 12 of the 17 factors compared between the two stocks.